Technology evaluation: HspE7 (Stressgen).
Stressgen is developing HspE7, a recombinant fusion protein comprising the human papillomavirus (HPV) E7 antigen and the heat shock protein Hsp65 from Mycobacterium bovis, as a potential therapy for conditions associated with HPV infection. This therapy is currently undergoing phase III clinical trials.
University of Pennsylvania, Department of Microbiology, 36th St and Hamilton Walk, Philadelphia, PA 19104-6076, USA.
Paulo Cesar
PC
Maciag
Yvonne
Y
Paterson
D000818:Animals; D001426:Bacterial Proteins / Q000235:genetics / Q000627:therapeutic use*; D018834:Chaperonin 60; D018833:Chaperonins / Q000235:genetics / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D009856:Oncogene Proteins, Viral / Q000235:genetics / Q000627:therapeutic use*; D050725:Papillomavirus E7 Proteins; D030361:Papillomavirus Infections / Q000188:drug therapy*; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000627:therapeutic use*
D001426:Bacterial Proteins; D018834:Chaperonin 60; D009856:Oncogene Proteins, Viral; D050725:Papillomavirus E7 Proteins; D011993:Recombinant Fusion Proteins; C074119:heat-shock protein 65, Mycobacterium; C059731:oncogene protein E7, Human papillomavirus type 16; D018833:Chaperonins